Foxby Corp Announces Temporary Stock Symbol Change Following Reverse Stock Split theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
IGM Biosciences Appoints George Gauthier as Chief Commercial Officer
Mr. Gauthier Brings 20 Years of Global Commercial Experience in the Life Sciences Industry
April 12, 2021 07:00 ET | Source: IGM Biosciences IGM Biosciences Mountain View, California, UNITED STATES
MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Chief Commercial Officer. Mr. Gauthier joins IGM with twenty years of experience in global commercial strategy, marketing, sales and product development. Most recently, Mr. Gauthier was Vice President of Global Product Strategy for Breast and Gynecological Cancers at Genentech, where he led a global team in the creation and execution of commercial and product development strategies.
Facedrive” or the “
Company”) (TSX-V: FD), a Canadian “people-and-planet first” tech ecosystem, today announced its year end fiscal 2020 (“
Fiscal 2020”) operational and financial results. All financial results are reported in Canadian dollars, unless otherwise stated.
Facedrive is a multi-faceted “people-and-planet first” tech ecosystem offering socially-responsible services to local communities with a strong commitment to doing business fairly, equitably and sustainably. As part of this commitment, Facedrive’s vision is to fulfil its mandate through a number of services and offerings that either leverage existing technologies of the Company or project initiatives with existing lines of business. Facedrive’s services and offerings include eco-friendly rideshare; food delivery services (Facedrive Foods); its Steer electric and hybrid vehicle subscription service; contact-tracing and connected health technology services (Facedrive Health); e-commerce; and e-so
(1)
Application based on positive Phase 1b/2 data from the CARTITUDE-1 study and follows confirmation of accelerated assessment by the Committee for Medicinal Products for Human Use of the European Medicines Agency
The Janssen Pharmaceutical Companies of Johnson Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma.
The application is supported by positive results from the ongoing Phase 1b/2 CARTITUDE-1 study, investigating the safety and efficacy of cilta-cel.
/PRNewswire/ - Trilogy Metals Inc. (TSX: TMQ) (NYSE American: TMQ) ("Trilogy Metals" or "the Company") announced today that the Company has amended its equity.